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Letters to the Editor 
TREATMENT OF CYCLOSPORIN-INDUCED 
HAEMOLYTIC URAEMIC SYNDROME WITH FKS06 
SIR,-Haemolytic uraemic syndrome (HUS) is a well~ 
recognised complication of cyclosporin therapy in organ 
transplantationKD~ It has usually been treated by a switch to 
azathioprine. We repon the first use ofFK506 in the management 
of this complication. A 33-year-old man had liver transplantation in 
January, 1989, for end-stage liver disease due to chronic active 
hepatitis. Recovery was complicated by acute tubular neaosis 
which required haemodialysis for 3 weeks. He was discharged 7 
weeks postoperatively with normal liver function, nonnal 
haematological profile, serum creatinine 2·4 mg/dl, and blood urea 
nitrogen (BUN) 24 mg/d1. His daily medications were cyclosporin 
600 mg, azathioprine 75 mg, acyclovir 200 mg, and trimethoprim 
80 mg plus sulphamethoxazole 400 mg. 
7 months postoperatively, he became anaemic with a haematocrit 
of 14,7%, platelet count of 29 OOO/j.LI,and white cell count 5BOO/j.LI. 
Total bilirubin rose to 5·7 mg/dl, creatinine to 5·0 mg/d1, and BUN 
to 69 mg/dl. His cyclosporin level, which was therapeutic, was 
713 ng/ml (TDX method). A blood smear revealed 
microangiopathic haemolytic anaemia. The urine contained trace 
protein and the sediment had 1-3 hyaline casts per high-power field. 
The patient was afebrile and without major complaints. Because of 
the microangiopathic haemolytic anaemia, thrombocytopenia, and 
renal failure, cyclosporin-induced HUS was diagnosed. 
When the platelet count and haematocrit continued to fall for 2 
days after admission, azathioprine and cyclosporin were 
discontinued. FK506 was started at 8 mg daily (0'15 mg/kg) 
intravenously and changed to 16 mg per day orally after 3 days. 
Within 24 h of the stan ofFK506 the platelet count had increased to 
130 OOO/j.LI, and by the seventh day it was 420 OOO/j.LI (figure). The 
haematocrit rose progressively, staning on day 6. Renal function 
initially worsened but also began to improve on day 7 of FK.S06 
therapy. Dialysis was not required. Total bilirubin fell promptly 
(figure). The patient was discharged after a week, and a week after 
this his serum creatinine was 4·2 mg/dl and platelet count 
420000/j.LI. 
After discharge, the dose of FK506 was arbitrarily halved. 4 
weeks later HUS abruptly recurred with thrombocytopenia, 
hyperbilirubinaemia, and acute renal failure. The oral FK506 dose 
was restored to 16 mg daily, with rcsclution of the HUS within a few 
days and during the ensuing 6 weeks. 
This patient quickly recovered from cyclosporin-induced HUS 
without the need for plasmapheresis or other ancillary therapy. 
Cyclopsorin-induced HUS is often fatalD~ and poor control of graft 
rejection accompanies the discontinuation of cyclosporin. In our 
patient the offending immunosuppressive agent was replaced by a 
more potent one. ' Cyclosporin and FK506 both inhibit interleukin-
2 production and binding and selectively suppress T-cell function. 
However, the two drugs have a completely different chemical 
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Hospital course of patient with c:yclosporin-induc:c:d HUS. 
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THE LANCET, DECEMBER 23/30, 1989 
strucrure, and thi.s may explain the salutary effects of FK506 in 
cyclosporin-induced HUS. 
Rapid recovery, as seen in this case, has been uncommon. 
Gradual improvement of the haematologicai picture has been the 
usual course as cyclosporin is cleared from the plasma with or 
without plasmapheresis. Cyclosporin-induced endothelial cell 
injury is the probable proximate event in the pathogenesis ofHUS 
in most cases. However, autoimmune haemolytic anaemia has also 
been described.6 •7 The ancillary manoeuvres used to treat 
cyclosporin-induced HUS are directed at immune mechanisms. 
FK506, the most potent immunosuppressant yet used clinically".a 
may exert its effect not only by substituting for cycJosporin but also 
by treating the primary immunological origin of this disorder. 
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aJNICAL TRIALS WITII ORAL IRON CHELATOR i1K/l~~;:K::·; 
'j".: •• ~ .... ,).<""' ... -:1. 
SIR,-Your Oct 28 editorial (p 1016) states that trials with the oral ~{:~DKlD;Dt1· 
iron chelator 1,2-d.imethyl-3- hydroxypyrid-4-0ne (Ll) should be<~ -~;D" 
suspended. A cheap, effective, and safe oral iron chelator is urgently. ,'::\ II~ .. 
needed, so we should examine carefully the evidence on which you KDiI~·t: 
base your advice to StOP trials with a low-cost drug that has already I:K€~Tii 
been shown to be orally effective at removing iron.'" You refer to :;Kt~~Kh· 
the development of agranulocytosis in 1 patient, joint pains in P~~~~C1DI 
patients, 2 deaths of patients who received the drug, and leuco~~~:; 
in rats and mice receiving subacute doses ofilK·::?:~·~A1:D--· 
At an international meeting in London (Nov 2-4, 1989), data OIl l;K~KD::D 
120 patients who have received L1 for between 1 and IS months :.';,,::" -
were presented. Apan from our 1 patient with Blackfan-Diamond': '. , 
anaemial no patient experienced a change in neutrophil,····,.,' ,-
lymphocyte, or platelet.count. Blackfan-Diamond anaemia is a 
condition in which neutropenia is well recognised: this single case 
does not argue for all trials to be abandoned though we would advise 
against the drug being given to other patients with the Blackfan-
Diamond anaemia, at least for the time being. 
Mild transient musculoskeletal aches were described in 3 of 24 
thalassaemia major patients treated in Bombay, and we have noted 
this in 3 of our patients." There is no direct evidence that th~ 
symptoms were drug induced and toxicity in the joints arising YllI 
iron complexes is unlikely to be correct since shon-tenn clinical 
trials in rheumatoid arthritis patients in the Netherlands revealed no 
such toxicityK~ . 
I of the 2 patients who died' was a total non-complier WIth 
subcutaneous desferrioxamine with gross iron overload, congesnve 
heart failure, cardiac arrhythmias, and diabetes who asked to be put 
on L 1. The chelator was taken for 2 months, but had not been taken 
for 6 weeks before her death from infection and cardiac failure. Her 
white cell count had not changed. Many other non-compliers with 
dcsferrioxamine have had cardiac failure, and this may not be 
reversible even by intravenous desferrioxamine at high doses. The 
second patient to die,S l weeks after stopping L 1. had progresSIVe 
myelodysplasia with increasing blasts in the marrow. not a situatlon 
